Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer

NCT00786006 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG: FOLFIRI.3
DRUG: FOLFOX

Sponsor

Asan Medical Center